MAYO CLINIC

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1889-01-01

Employees: 10K

Market Cap: -

Website: http://www.mayoclinic.org

Clinical Trials

Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer

Not Applicable

Completed

Conditions: Osteoporosis
Breast Cancer

Interventions: Drug: zoledronic acid
Procedure: Letrozole as adjuvant therapy

First Posted Date: 2007-02-19

Last Posted Date: 2019-09-11

Lead Sponsor: Mayo Clinic

Target Recruit Count: 60

Registration Number: NCT00436917

Locations: 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders

Early Phase 1

Completed

Conditions: Chronic Myeloproliferative Disorders
Leukemia

Interventions: Drug: PS-341

First Posted Date: 2007-02-19

Last Posted Date: 2014-10-17

Lead Sponsor: Mayo Clinic

Target Recruit Count: 30

Registration Number: NCT00437086

Locations: 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: Alemtuzumab
Drug: Rituximab

First Posted Date: 2007-02-19

Last Posted Date: 2011-12-01

Lead Sponsor: Mayo Clinic

Target Recruit Count: 30

Registration Number: NCT00436904

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Does DHEA Enhance the Effects of Exercise in Postmenopausal Women?

Not Applicable

Completed

Conditions: Aging

First Posted Date: 2007-02-14

Last Posted Date: 2011-03-23

Lead Sponsor: Mayo Clinic

Target Recruit Count: 32

Registration Number: NCT00434915

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Weight Loss in Response to Sibutramine (MERIDIA) is Influenced by the Inherited Genes

Phase 4

Completed

Conditions: Obesity

Interventions: Drug: sibutramine

First Posted Date: 2007-02-12

Last Posted Date: 2011-03-14

Lead Sponsor: Mayo Clinic

Target Recruit Count: 181

Registration Number: NCT00433641

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Drug: Thalidomide
Drug: zoledronic acid

First Posted Date: 2007-02-07

Last Posted Date: 2012-07-04

Lead Sponsor: Mayo Clinic

Target Recruit Count: 68

Registration Number: NCT00432458

Locations: 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸
Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic - Jacksonville, Jacksonville, Florida, United States

and more 1 locations

Steady-State Feedback Actions of Testosterone on Luteinizing Hormone Secretion in Young and Older Men

Phase 1

Completed

Conditions: Hypogonadism

First Posted Date: 2007-02-05

Last Posted Date: 2010-01-28

Lead Sponsor: Mayo Clinic

Target Recruit Count: 40

Registration Number: NCT00431197

Locations: 🇺🇸
Mayo Clinic and Foundation, Rochester, Minnesota, United States

Skin Conduction Device and Patient Diary for Measuring Hot Flashes in Postmenopausal Women With Hot Flashes

Not Applicable

Completed

Conditions: Hot Flashes

First Posted Date: 2007-01-29

Last Posted Date: 2011-03-17

Lead Sponsor: Mayo Clinic

Target Recruit Count: 3

Registration Number: NCT00427531

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Skin Conduction Device for Measuring Hot Flashes in Postmenopausal Women With Hot Flashes

Not Applicable

Completed

Conditions: Hot Flashes

First Posted Date: 2007-01-29

Last Posted Date: 2014-04-09

Lead Sponsor: Mayo Clinic

Target Recruit Count: 25

Registration Number: NCT00427622

Locations: 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States

Octreotide in Severe Polycystic Liver Disease

Phase 2

Completed

Conditions: Polycystic Kidney, Autosomal Dominant
Polycystic Liver Disease
Hepatomegaly
Liver Diseases
Kidney, Polycystic
Abdominal Pain

Interventions: Drug: Octreotide
Drug: Placebo

First Posted Date: 2007-01-24

Last Posted Date: 2012-11-21

Lead Sponsor: Mayo Clinic

Target Recruit Count: 42

Registration Number: NCT00426153

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy